Gender | Age | Adenocarcinoma of prostate
Item
males greater than or equal to 18 years of age with histologically confirmed adenocarcinoma of the prostate.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0007112 (UMLS CUI [3])
Study Subject Participation Status | TARP Peptide Vaccine
Item
prior enrollment in nci protocol 09-c-0139 with receipt of at least 5 doses of tarp peptide vaccine (i.e. completion of primary vaccination series).
boolean
C2348568 (UMLS CUI [1])
C0960676 (UMLS CUI [2,1])
C0599934 (UMLS CUI [2,2])
ECOG performance status | Life Expectancy
Item
performance status: ecog 0-1, life expectancy of greater than or equal to 1 year.
boolean
C1520224 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
Hemoglobin | White Blood Cell Count procedure | Absolute lymphocyte count | Absolute neutrophil count | Platelet Count measurement
Item
hemoglobin greater than or equal to 10.0 gm/dl, wbc greater than or equal to 2,500/mm3, alc greater than or equal to 500/mm3, anc greater than or equal to 1,000/mm3, platelet count greater than or equal to 100,000/mm3.
boolean
C0019046 (UMLS CUI [1])
C0023508 (UMLS CUI [2])
C3544087 (UMLS CUI [3])
C0948762 (UMLS CUI [4])
C0032181 (UMLS CUI [5])
Prothrombin time | Partial Thromboplastin Time measurement | Anticoagulant therapy
Item
pt/ptt less than or equal to 1.5x uln unless receiving clinically indicated anticoagulant therapy.
boolean
C0033707 (UMLS CUI [1])
C0030605 (UMLS CUI [2])
C0150457 (UMLS CUI [3])
Aspartate Transaminase | Alanine Transaminase | Bilirubin, total measurement | Creatinine measurement | Estimated Glomerular Filtration Rate
Item
sgot/sgpt less than or equal to 2.5x uln, total bilirubin less than or equal to 1.5x uln, cr less than or equal to 1.5x uln, estimated gfr (egfr) greater than or equal to 60 ml/min.
boolean
C0004002 (UMLS CUI [1])
C0001899 (UMLS CUI [2])
C0201913 (UMLS CUI [3])
C0201975 (UMLS CUI [4])
C3811844 (UMLS CUI [5])
Hepatitis B test negative | Hepatitis C test negative
Item
hepatitis b and c negative, unless the result is consistent with prior vaccination or prior infection with full recovery.
boolean
C1611173 (UMLS CUI [1])
C1619717 (UMLS CUI [2])
HIV negative
Item
hiv negative
boolean
C0481430 (UMLS CUI [1])
Investigational New Drugs Not used | Immunosuppressive Agents | Biological Response Modifiers | Immunoglobulins, Intravenous
Item
no use of investigational agents within 4 weeks of study enrollment or use of immunosuppressive or immunomodulating agents (including ivig) within 8 weeks of study entry. note: use of topical, inhaled and intranasal steroid therapy is permitted.
boolean
C0013230 (UMLS CUI [1,1])
C0445107 (UMLS CUI [1,2])
C0021081 (UMLS CUI [2])
C0005525 (UMLS CUI [3])
C0085297 (UMLS CUI [4])
Chemotherapy | Therapeutic radiology procedure
Item
greater than or equal to 6 weeks since the receipt of chemotherapy or radiation therapy.
boolean
C3665472 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
Prostate carcinoma | Standard of Care | Antiandrogen therapy
Item
standard of care medical management of current prostate cancer disease status by the patient s local oncologist, e.g. androgen deprivation therapy is allowed.
boolean
C0600139 (UMLS CUI [1])
C2936643 (UMLS CUI [2])
C0279492 (UMLS CUI [3])
Informed Consent
Item
able to understand and provide informed consent.
boolean
C0021430 (UMLS CUI [1])
Compliance behavior Study Protocol
Item
must be able and willing to adhere to protocol requirements, visits and vaccination
boolean
C1321605 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Timeline
Item
timeline.
boolean
C1705821 (UMLS CUI [1])
Neoplasms, Second Primary Requirement Therapeutic procedure
Item
patients with a second malignancy requiring active treatment.
boolean
C0085183 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
Communicable Diseases
Item
patients with an active infection.
boolean
C0009450 (UMLS CUI [1])
Therapeutic immunosuppression
Item
patients on immunosuppressive therapy including:
boolean
C0021079 (UMLS CUI [1])
Steroid therapy Systemic | inhaled steroids | Adrenal Cortex Hormones Intranasal | Topical corticosteroids
Item
-systemic corticosteroid therapy for any reason. patients receiving inhaled, intranasal or topical corticosteroids may participate.
boolean
C0149783 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C2065041 (UMLS CUI [2])
C0001617 (UMLS CUI [3,1])
C0001560 (UMLS CUI [3,2])
C0304604 (UMLS CUI [4])
Illness Significant | Illness Uncontrolled | Mild asthma
Item
other significant or uncontrolled medical illness. patients with a remote history of or active mild asthma may participate.
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0221423 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0581124 (UMLS CUI [3])
Problem Medical | Psychosocial problem
Item
patients who, in the opinion of the principal investigator, have significant medical or psychosocial problems that warrant exclusion including:
boolean
C0033213 (UMLS CUI [1,1])
C0205476 (UMLS CUI [1,2])
C0740697 (UMLS CUI [2])
medical condition Serious
Item
other serious non-malignancy-associated medical conditions that may be
boolean
C1699700 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Life Expectancy
Item
expected to limit life expectancy to less than 2 years.
boolean
C0023671 (UMLS CUI [1])